Crossmark

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Crossref DOI link: https://doi.org/10.1186/s10194-020-01162-x

Published Online: 2020-08-12

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hansson-Hedblom, Amanda

Axelsson, Isabelle http://orcid.org/0000-0002-3629-5635
Jacobson, Lena

Tedroff, Joakim

Borgström, Fredrik
Funding

Funding for this research was provided by:

Allergan Norden AB
License Information

Text and Data Mining valid from 2020-08-12

Version of Record valid from 2020-08-12
More Information

Article History

Received: 29 May 2020

Accepted: 17 July 2020

First Online: 12 August 2020

Ethics approval and consent to participate

: Ethics approval: Diarienr 2018/1065–31/5. Regionala etikprövningsnämnden i Stockholm.Informed consent was obtained from all study participants.

: All data analysed in this study were deidentified and results only presented on an aggregate level. Informed consent was obtained from all study participants prior to participation, and ethics approval was obtained.

: IA, FB and AH are employees of Quantify Research which was contracted and paid by Allergan Norden AB to conduct the study. The authors did not receive direct payment as a result of this work outside of their normal salary payments. LJ is an employee of Allergan Norden AB. JT has received compensation for lectures, educational efforts and consulting activities from Allergan Norden AB.

Document is current

Any future updates will be listed below